Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Innovative Imperial spin-out biopharmaceutical company teams up with BioVectra

08.08.2007
PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, today announced that it has signed a manufacturing and bilateral representation agreement with BioVectra dcl, a Canadian biopharmaceutical company that supplies specialty chemicals and contract manufacturing services to the pharmaceutical and biotechnology industry.

The agreement, which follows hard on the heels of PolyTherics’ recent successful fundraising of over £2 million, will see BioVectra manufacturing high quality cGMP MPEG reagents to support clients’ clinical development of PolyTherics’ novel PEGylation technology. BioVectra will also market the PEGylation technology to its client base in North America.

PolyTherics has developed patent-protected proprietary technologies and expertise in the modification of drugs to improve their performance. The Company’s innovative PEGylation technology, known as TheraPEG, can extend the half-life of novel and existing protein drugs. The TheraPEG approach produces an improvement in biological activity and a higher yield than the existing PEGylation technologies. This means that drugs, such as Interferon, stay active in the body for longer, enabling longer periods between doses. Patients can therefore be treated less often, with fewer side-effects and at lower cost.

The market for traditional PEGylation has expanded considerably and PolyTherics’ TheraPEG technology is positioned both to address existing markets and open new markets, particularly in the antibody field. PolyTherics already has revenue-generating development contracts in place with several companies and is in discussion with a number of other parties.

Dr Keith Powell, CEO of PolyTherics, said: “We are delighted to have signed this agreement with BioVectra, who offer access to specialist custom polymer chemistry capabilities, a patented MPEG purification process and scaled manufacturing systems –the key components that are needed to support clients of our TheraPEG™ technology.

“We are currently in discussion with a number of biogeneric and pharmaceutical companies in Europe and the USA and there is significant interest in downstream applications for our TheraPEG technology. This agreement with BioVectra means that we can work with a highly competent manufacturer who will supply the highest quality MPEGs to meet our clients’ needs and comply with FDA standards. So we now have the tools to take our TheraPEG™ technology from the laboratory into the feasibility testing and manufacturing stages.”

Stephen Ball, Business Development Representative for BioVectra, said: “We are pleased to be working with PolyTherics to support the development of their innovative and important site specific TheraPEG technology. We look forward to deploying our capabilities in the manufacturing of high quality cGMP MPEG reagents to assist PolyTherics’ clients through clinical development of therapeutic proteins into post approval commercialization.”

Dale Zajicek, Chief Operating Officer of BioVectra, said: “We remain committed to supporting our PEGs business initiatives with technology that creates true value for our customers and their patients. The PolyTherics agreement is a clear example of this commitment.”

Margaret Henry | alfa
Further information:
http://polytherics.co.uk

More articles from Life Sciences:

nachricht When Air is in Short Supply - Shedding light on plant stress reactions when oxygen runs short
23.03.2017 | Institut für Pflanzenbiochemie

nachricht WPI team grows heart tissue on spinach leaves
23.03.2017 | Worcester Polytechnic Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

When Air is in Short Supply - Shedding light on plant stress reactions when oxygen runs short

23.03.2017 | Life Sciences

Researchers use light to remotely control curvature of plastics

23.03.2017 | Power and Electrical Engineering

Sea ice extent sinks to record lows at both poles

23.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>